Charming Medical Ltd

Charming Medical Ltd (MCTA) News & Events

$29.355

+1.981 (+6.75%)At close

MCTA News

MCTA Events

11/26 07:08

Nasdaq Suspends Trading of Charming Medical

The Nasdaq Stock Market announced that trading is halted in Charming Medical for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in MCTA from 04:00:00 on November 12, 2025 to 23:59:00 on November 25, 2025. The last sale price of the company's ordinary shares was $29.355.

11/12 11:10

SEC Directs Suspension of Trading for Charming Medical Securities

The SEC states in an order: "It appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension in the trading of the securities of Charming Medical Limited, a holding company incorporated in the British Virgin Islands and headquartered in Hong Kong, because of potential manipulation in the securities of MCTA effectuated through recommendations made to investors by unknown persons via social media to purchase, hold, and/or sell the securities of MCTA and to send screenshots documenting their transaction, which appear to be designed to artificially inflate the price and trading volume of the securities of MCTA. As of November 10, 2025, the common stock of MCTA is listed on the Nasdaq Capital Market under the symbol "MCTA." The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company." It is ordered that trading in the securities is suspended for the period from 4:00 AM ET on November 12, 2025, through 11:59 PM ET on November 25, the SEC noted.

10/21 12:00

Charming Medical Debuts at $4.59 After IPO Set at $4.00 per Share

Charming Medical, a Hong Kong-based provider of Traditional Chinese Medicine-inspired therapies and products, priced its initial public offering of 1.6M Class A ordinary shares at a price of $4.00 per share. The company intends to use the net proceeds from the offering for expanding its business and geographic coverage, potential strategic investments and acquisitions, research and development, and for general working capital and corporate purposes. Cathay Securities is acting as the representative of the underwriters for the offering.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started